ProMIS Neurosciences Inc.
corporate_fare Company Profile
ProMIS Neurosciences Inc. (NASDAQ:PMN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for PMN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for PMN spans 8-K, 10-Q, DEF 14A, S-3.
Recent high-impact activity:
- ProMIS Posts Q3 2026 Results; $44.1M Cash Funds Operations Through 2027
- ProMIS Reports Q2 2026 Results: $53.4M Cash Runway Through 2027, Net Loss Narrows Per Share
- PMN310 Shows Zero ARIA-E in Alzheimer's Trial, Early Biomarker Signal Positive
- Shareholders Approve 10% Potential Dilution for Stock Option Plan
- ProMIS Neurosciences Reports Q1 Results, Confirms $70.1M Net Proceeds from PIPE, Extends Cash Runway Through 2027
Financial Snapshot
Short Interest & Short Volume
1.54 days to coverFINRA reported short interest of 274,761 shares in PMN as of the October 30, 2026 settlement, a 11.8% increase from the prior period — about 1.5 days to cover at its recent average daily volume. On November 19, 2026, 60.9% of PMN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.